ReviewFrontiers in pharmacology2026
Therapeutic advances in traditional Chinese and Tibetan medicine for high-altitude cerebral edema.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: High-altitude cerebral edema (HACE) is an exacerbation of acute mountain sickness, but also a distinct disease characterized by vasogenic and cytotoxic brain edema. Exploring alternative therapies, such as traditional Chinese medicine (TCM) and Tibetan medicine (TM), is important. We aimed to provide a comprehensive overview of the existing research on the therapeutic effects and underlying molecular mechanisms of TCM and TM, encompassing herbal formulations, single botanical drugs, and their bioactive Methods: We employed keywords such as "TCM," "TM," "Botanical drug," "HACE," and "Hypoxia" to systematically retrieve studies on the therapeutic use of TCM and TM for HACE published up to May 2025, in databases including Web of Science, PubMed, China National Knowledge Infrastructure (CNKI) and Wanfang Data. Results: We conducted analysis of 97 research articles, encompassing the latest advancements in the treatment of HACE using 4 TCM formulations, 12 single botanical drugs of TCM, 3 TM formulations, and five single botanical drugs of TM. Sources, effects, and molecular mechanisms of the TCM and TM were summarized. Discussions: We report the progress of traditional botanical drugs and their formulations derived from TCM and TM in the management of HACE, based on the medical practices and materia medica from the high mountain regions in Eastern Asia. We provide a foundation for the clinical application and further development of these medicinal resources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.